BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS) is pleased to announce the production of zirconium-89 (89Zr) oxalate using a low energy medical cyclotron in a US based commercial nuclear pharmacy. The production yielded in excess of 40 millicuries of 89Zr after a 60 minute, low activity irradiation of ARTMS’ yttrium-89 solid target. ARTMS’ QUANTM Irradiation System (QIS™) enables commercial nuclear pharmacies to produce 89Zr locally and relieve the reliance on centrally produced isotopes. ARTMS is focused on increasing access to high quality and high yield key isotopes like zirconium-89, gallium-68 and copper-64 with other isotopes in development.
“ARTMS has enjoyed success in 2021 by partnering with US Commercial radiopharmacies and enabling them to control their isotope supply chain. This latest news on 89Zr speaks to the capability and versatility of the QISTM ecosystem that ARTMS has assembled/pioneered. Zirconium-89, gallium-68 and copper-64 are critically important to more precisely diagnose medical conditions in patients and will drive the future of Nuclear Medicine. ARTMS is expanding the reach of our partners by leading the way in decentralized production of commercially relevant volumes of these exciting and medically important imaging isotopes,” explained Charles S. Conroy, Chief Executive Officer of ARTMS.
“This is the next step towards the realization of on demand next generation PET diagnostic products for the patients who need them most,” said Mark Przekop, Chief Product Officer of ARTMS. “Zirconium-89 has a number of diagnostic clinical applications and will potentially contribute to the health of millions of patients globally. ARTMS and its partners are proud of this latest accomplishment and look forward to the next set of irradiations of our QUANTM solid targets for both commercial and clinical research purposes.”
Conroy added, “The ARTMS platform goes far beyond 89Zr production, expanding our client’s reach to other high demand diagnostic and therapeutic isotopes. The future is bright for ARTMS and our partners.”
With a focus on optimizing production potential, ARTMS will continue the development of cyclotron-produced 89Zr and other vitally important medical isotopes, while also pursuing multiple regulatory approvals. ARTMS has a variety of solid targets commercially available used in combination with ARTMS’ QUANTM Irradiation System (QISTM).
About ARTMS
Based in Burnaby, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.
For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter @Quantm99 and LinkedIn and visit http://www.artms.ca/
